BIOT Investor Facts
Verified entity information for INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT), organized for investors, search engines and AI systems. Every figure is published together with its as-of date and source.
Entity Information
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. ("BIOT") is a Cayman Islands-incorporated holding company whose ordinary shares trade on The Nasdaq Stock Market under the ticker symbol BIOT. The group operates businesses originating in Japan across research and development, sourcing, manufacturing, regenerative medicine-related technologies, cosmetics, wellness and consumer brands.
Key Facts
- Legal Name
- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
- Abbreviation
- BIOT
- Ticker Symbol
- BIOT (ordinary shares) / BIOTW (warrants)
- Exchange
- The Nasdaq Stock Market
- Listing Date
- July 24, 2026
- Jurisdiction of Incorporation
- Cayman Islands
- Registered Office
- 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands
- SEC Reporting Status
- Foreign Private Issuer
- Commission File Number
- 001-43415
- Fiscal Year End
- November 30
- Accounting Standards
- IFRS as issued by the IASB
- Official Website
- https://instinct-biot.com/
- Investor Relations
- https://instinct-biot.com/ir
- IR Contact
- ir@instinct-bro.com
Capital Structure & Major Shareholders
Each figure below is stated as of the date shown and does not reflect changes after that date. For the most recent information, refer to the applicable SEC filing.
Figures with As-Of Dates
- Shares outstanding
- 28,794,472 ordinary sharesAs of: July 23, 2026
Source: SEC Form 20-F (shell company report, filed July 29, 2026) - Beneficial ownership — Tomoki Nagano (Chairman & CEO)
- 10,425,365 ordinary shares (36.21%)As of: July 23, 2026
Source: SEC Form 20-F - Beneficial ownership — Relativity Acquisition Sponsor, LLC
- 5,515,481 ordinary shares (19.15%)As of: July 23, 2026
Source: SEC Form 20-F - Beneficial ownership — Chardan Capital Markets LLC
- 1,615,385 ordinary shares (5.61%)As of: July 23, 2026
Source: SEC Form 20-F
Leadership
| Name | Role |
|---|---|
| Tomoki Nagano | Chairman & CEO |
| Yuji Naito | Director & COO |
| Fumihiro Nagano | Director & CMO |
| Masato Terachi | Independent Director |
| Say Leong Lim | Independent Director |
| Sally Lim | Independent Director |
| Jessica Assaf | Independent Director |
| Masashi Ohmatsu | Executive Officer & CFO |
| Futa Sakakibara | Chief Technical Officer |
| Kenta Nakajima | Executive Officer, Head of Manufacturing (Japan & International) |
| Takashi Bota | Executive Officer, Head of Sales & Head of Value Athlete Division |
| Koichiro Maruta, M.D. | Special Advisor, Regenerative Medicine |
| M. D. Daniel Hadinoto, MD | Medical Advisor (Indonesia) |
| Akemi Yamaguchi | Femcare Strategy Advisor |
Advisors are neither directors nor executive officers and hold no voting rights on the board.
Group Companies
Source Documents
Source Documents
Investor Contact
For investor inquiries, contact {IR_EMAIL} or call {PHONE}. You can also use our contact form.
Last updated: